Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

Italian researchers have developed a nasal spray showing promise in slowing Alzheimer's progression. Tests on mice with ...

Subtle signs of Alzheimer's disease can emerge decades before a diagnosis—often in the form of irregular behaviors that ...

I want to express my gratitude to Sen. Bob Casey for his steadfast dedication to the fight against Alzheimer’s disease during ...

Americans 65 and older have Alzheimer’s, which is why it’s so important for us to have tips and tricks for keeping them safe ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, ...